Samples should arrive within the laboratory within 72 hours of collection.
If sample cannot be sent immediately after bleeding, keep in 4 degree fridge and send as soon as possible.
FLT3 (fms-related tyrosine kinase 3) is the most commonly mutated gene in human acute myeloid leukemia (AML) and has been implicated in its pathogenesis. FLT3 is a receptor tyrosine kinase that is expressed on early hematopoietic progenitor cells, where it mediates differentiation and proliferation. Two different types of functionally important FLT3 mutations that lead to constitutive activation of the FLT3 protein have been identified. Internal tandem duplication (ITD) mutations of 3-400 bp (always in-frame) that map to the juxta-membrane domain encoded by exons 14 and 15 of FLT3 have been described in 15-25% of patients with AML. It is now broadly agreed that FLT3-ITD mutations in general are associated with inferior outcome, although several other important factor might modulate the prognostic impact of FLT3 ITD.
Contact HODS Molecular Biology Lab for further enquiries on Ext. 4326.
